Virology Core C is the central point of the Program Project for specimen handling, storage and distribution from the domestic Clinical Core B (Figure 1). Scientifically, it is devoted to definition and dissection of HIV-1 levels, resistance states and the anatomic locations of HIV among participants enrolled and followed in this Program. This core is essential to and tightly integrated with the other cores and projects. After delivery from the clinic the samples are stored in the repository and can be retrieved and routed to the requestor quickly. Viral load results are sent to Admin Core A and Clinical Core B. Currently, the repository occupies five -80 freezers and four LN2 tanks. While existing space can handle additional plasma samples, another LN2 tank is required to store new cell samples that will be collected. Much of the emphasis of our work over the last 5 years has been to define sites and mechanisms of HIV-1 persistence during the course of antiretroviral therapy. We were first to show that viral latency in T cells is established early after infection^ and one of the first groups to demonstrate that continued low-grade virus replication is confined to specific cell types during the course of HAART^'. Understanding what factors influence persistence of HIV-1 replication is an ongoing emphasis of our laboratories"'^. Many of the specific aims in this program are directed at virological and immunological factors that influence HIV-1 dynamics. As such, we have spent considerable time developing quantitative, reproducible, and sensitive assays that can measure HIV-1 at different stages of the virus cycle and in a variety of tissues and cell types.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI057005-09
Application #
8508170
Study Section
Special Emphasis Panel (ZCA1-GRB-T)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
9
Fiscal Year
2013
Total Cost
$97,621
Indirect Cost
$25,432
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Hu, Xintao; Valentin, Antonio; Dayton, Frances et al. (2016) DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV. J Immunol 197:3999-4013
Johnston, Christine; Harrington, Robert; Jain, Rupali et al. (2016) Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 22:149-56
Ma, Qing; Vaida, Florin; Wong, Jenna et al. (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 22:170-8
Mothe, Beatriz; Hu, Xintao; Llano, Anuska et al. (2015) A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med 13:60
Iyer, Shyamala; Casey, Eleanor; Bouzek, Heather et al. (2015) Comparison of Major and Minor Viral SNPs Identified through Single Template Sequencing and Pyrosequencing in Acute HIV-1 Infection. PLoS One 10:e0135903
Manocheewa, Siriphan; Mittler, John E; Samudrala, Ram et al. (2015) Composite Sequence-Structure Stability Models as Screening Tools for Identifying Vulnerable Targets for HIV Drug and Vaccine Development. Viruses 7:5718-35
Manocheewa, Siriphan; Lanxon-Cookson, Erinn C; Liu, Yi et al. (2015) Pairwise growth competition assay for determining the replication fitness of human immunodeficiency viruses. J Vis Exp :e52610
Stekler, Joanne D; McKernan, Jennifer; Milne, Ross et al. (2015) Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 20:77-80
Sunshine, Justine E; Larsen, Brendan B; Maust, Brandon et al. (2015) Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection. J Virol 89:10303-18
Maenza, Janine; Tapia, Kenneth; Holte, Sarah et al. (2015) How often does treatment of primary HIV lead to post-treatment control? Antivir Ther 20:855-63

Showing the most recent 10 out of 95 publications